Budesonide Inhalation Suspension, 1mg/2mL recall — Sun Pharmaceutical Industries Inc (Class II)
Sun Pharmaceutical Industries Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Budesonide Inhalation Suspension, 1mg/2mL — a Class II recall, initiated 2026-05-29 and posted to the FDA enforcement report on 2026-06-17, under recall number D-0607-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Presence of Foreign Substance:This recall has been initiated in response to a product quality complaint reported for black/brown specs and particles within the ampoule solution”. From the product description, the form is suspension, the strengths given are 1mg/2mL and 2 mL and the package is described as 5 Single-Dose Ampules and 6 pouches per carton. 1 National Drug Code number is printed in the record: 47335-633-49. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99113. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0607-2026 |
|---|---|
| FDA event ID | 99113 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Sun Pharmaceutical Industries Inc |
| Recall initiated | 2026-05-29 |
| Reported by FDA | 2026-06-17 |
| Report lag | 19 days from initiation to report |
| Distribution | Nationwide within the United States — Nationwide (US) |
| Firm location on record | NJ, United States |
| Product description (source) | Budesonide Inhalation Suspension, 1mg/2mL, 30 x 2 mL Sterile Single-Dose Ampules (5 Single-Dose Ampules per pouch, 6 pouches per carton, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited, Baska Ujeti Road, Ujeti Halol-289350, Gujarat, India, NDC 47335-633-49. |
Reason reported by FDA
Presence of Foreign Substance:This recall has been initiated in response to a product quality complaint reported for black/brown specs and particles within the ampoule solution
25 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
8 identifying values matched by exact pattern in the 44-word product description above; each is a literal substring of it.
| Product named | Budesonide Inhalation Suspension |
|---|---|
| Form | Suspension |
| Strength | 1mg/2mL · 2 mL |
| Package | 5 Single-Dose Ampules · 6 pouches per carton |
| NDC | 47335-633-49 |
| Manufactured by | Sun Pharmaceutical Industries Limited, Baska Ujeti Road |
| Distributed by | Sun Pharmaceutical Industries, Inc. |
Other indexed recalls from Sun Pharmaceutical Industries Inc
6 indexed records name Sun Pharmaceutical Industries Inc as the recalling firm, across 5 FDA events, reported 2026-06-10 to 2026-07-08. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Fexofenadine Hydrochloride Tablets, 180 mg | D-0654-2026 | Class III | 180 mg · Tablets | 2026-07-08 |
| Perampanel CIII Tablets, 6mg | D-0628-2026 | Class II | 6mg · Tablets | 2026-07-01 |
| DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL | D-0580-2026 | Class I | 50 mg/25 mL · Injection | 2026-06-17 |
| Xyvona (levorphanol tartrate tablets), 2mg | D-0598-2026 | Class II | 2mg · Tablets | 2026-06-10 |
| Xyvona (levorphanol tartrate tablets), 3mg | D-0599-2026 | Class II | 3mg · Tablets | 2026-06-10 |
Reported in the same month (2026-06)
74 enforcement reports carry a report date in 2026-06; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Duloxetine Delayed-Release Capsules, 30mg | D-0582-2026 | Breckenridge Pharmaceutical, Inc. | Class II | 2026-06-17 |
| Duloxetine Delayed-Release Capsules, 60mg | D-0583-2026 | Breckenridge Pharmaceutical, Inc. | Class II | 2026-06-17 |
| Zep, 70% | D-0586-2026 | Zep Inc | Class II | 2026-06-17 |
| GSMS Incorporated, 1,000 MG | D-0587-2026 | Golden State Medical Supply Inc. | Class II | 2026-06-17 |
| Minocycline Hydrochloride Extended-Release Tablets, 115 mg | D-0597-2026 | Ascend Laboratories, LLC | Class II | 2026-06-17 |
| Lidocaine HCl Injection USP | D-0554-2026 | Spectra Medical Devices, LLC | Class II | 2026-06-10 |
| Duloxetine DR Capsules, 30 mg | D-0555-2026 | Asclemed Usa Inc. | Class II | 2026-06-10 |
| Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg | D-0556-2026 | Ascend Laboratories, LLC | Class II | 2026-06-10 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 3 nearest to 2026-06-17 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| KIRKLAND Signature, 1000 mg | D-0557-2026 | Guardian Drug Co. Inc. | 1000 mg | 2026-06-10 |
| HALEON CALCIUM CARBONATE TUMS ANTACID, 1000 mg | D-0558-2026 | Guardian Drug Co. Inc. | 1000 mg · Tablets | 2026-06-10 |
| HALEON CALCIUM CARBONATE TUMS ANTACID, 750 mg | D-0559-2026 | Guardian Drug Co. Inc. | 750 mg · Tablets | 2026-06-10 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 47335-633-49 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Sun Pharmaceutical Industries Inc (6 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0607-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0607-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-06-17
- Ingested
- 2026-08-22
- Record hash
cc42f357dec97c78
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.